| P2093 | author name string | Masayoshi Soma | |
| | Kazuyoshi Okada | |
| | Masanori Abe | |
| | Hiroko Suzuki | |
| | Noriaki Maruyama | |
| | Yuki Fujii | |
| | Shiro Matsumoto | |
| | Terumi Higuchi | |
| | Mari Mizuno | |
| | Midori Ito | |
| P2860 | cites work | Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients | Q46112557 |
| | Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study | Q46173714 |
| | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy | Q46173838 |
| | Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes | Q46649728 |
| | Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis | Q46743392 |
| | Standards of medical care in diabetes--2008. | Q46828447 |
| | Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. | Q51364313 |
| | Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. | Q51919945 |
| | Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection | Q79700757 |
| | DPP-4 inhibitors and their potential role in the management of type 2 diabetes | Q28271159 |
| | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 |
| | Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects | Q33156176 |
| | Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy | Q34689865 |
| | Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies | Q35005772 |
| | Oral antihyperglycemic agents and renal disease: new agents, new concepts | Q36153042 |
| | Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug | Q36735761 |
| | Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors | Q36861085 |
| | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study | Q36975695 |
| | Pharmacokinetics of dipeptidylpeptidase-4 inhibitors | Q37768821 |
| | Alogliptin: a review of its use in the management of type 2 diabetes mellitus | Q37794971 |
| | Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice | Q37837923 |
| | Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis | Q42872976 |
| | Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia | Q43275817 |
| | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. | Q43299563 |
| | Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes? | Q46091498 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | alogliptin | Q4734170 |
| | patient | Q181600 |
| P304 | page(s) | 259-267 | |
| P577 | publication date | 2013-01-07 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis | |
| P478 | volume | 14 | |